Answers are grounded in this paper and cite their sources.
The management of a small intratesticular mass depends on whether it is genuinely indeterminate or suspicious for malignancy; normal serum tumour markers do not resolve that distinction.This narrative review compares the European Association of Urology (EAU) 2026-and American Urological Association (AUA) 2023-amended recommendations and examines the evidence supporting surveillance, additional imaging and testis-sparing surgery.Official guidelines and relevant clinical studies were reviewed through 12 October 2026, with attention to enrolment phenotype, histological verification and procedural sampling.Both guidelines favour radical inguinal orchidectomy for a mass considered malignant.For indeterminate findings with normal alpha-fetoprotein and human chorionic gonadotrophin, the AUA specifies repeat imaging after six to eight weeks and sets explicit eligibility criteria for testis-sparing surgery; the EAU supports selective magnetic resonance imaging and enucleation with frozen-section examination in appropriately selected masses.Surveillance cohorts largely comprise incidental, non-palpable lesions below 1 cm.Their low observed event rates cannot be extrapolated to symptomatic, enlarging or otherwise suspicious masses.Imaging accuracy studies assess characterisation, not comparative patient outcomes from competing pathways, while high frozen-section accuracy derives from targeted excisional sampling.Inflammatory disease may mimic a neoplasm or coexist with one; a benign result from limited tissue does not necessarily account for a persistently suspicious radiological target.Guideline interpretation should therefore begin with lesion phenotype and, when pathology and imaging disagree, return to whether the relevant abnormality was adequately represented.
No takes yet. Share an insight, caveat, or question.
Gad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: